What is the most direct and classic breakthrough direction in the R&D of brightening skincare products? For all researchers dedicated to skin brightening, tyrosinase inhibition pathway is invariably the primary option that comes to mind.

As the rate-limiting enzyme in melanin biosynthesis, tyrosinase can catalyze the conversion of tyrosine to dopa ( DOPA ) and subsequent oxidation products, so inhibiting its activity has become the most classic breakthrough direction. From the perspective of the mechanism of action, there are four main paths in the current product components : the first is to directly inhibit the enzyme activity. The inhibitor blocks the binding of the substrate ( tyrosine ) to the enzyme by competitively binding to the active site of tyrosinase, so that the key step of melanin synthesis is blocked. The second is the chelation of copper ions, because the active center of tyrosinase contains copper ions, some components can chelate these copper ions, so that the enzyme loses activity ; the third is the down-regulation of gene expression. With the help of signal pathway regulation, the expression of tyrosinase gene is reduced, and the number of enzymes is reduced from the source. The fourth is the change of enzyme conformation, which induces the conformational change of tyrosinase and reduces its catalytic activity.

These four mechanisms have different emphases. In the application of specific components, they are divided into traditional inhibitors, new synthetic inhibitors and natural source inhibitors, with different characteristics. Among the traditional inhibitors, Kojic acid directly inhibits enzyme activity by chelating copper ions, which can effectively reduce melanin synthesis and improve the problem of uneven skin color. However, as an early brightening ingredient, Kojic acid is now gradually replaced. It is also because it has obvious shortcomings. Its warmth is not good. Long-term use may cause contact dermatitis, allergies, erythema, etc., and poor light stability. It is also easy to oxidize, which is not conducive to storage and product stability, limiting its application in formulations and products. Hydroquinone can directly inhibit tyrosinase activity, and the brightening effect is very significant and even can be decolorized, but the controversy on hydroquinone is particularly large, because it has cytotoxicity to melanocytes and may induce mammalian cell mutations. Long-term use can also lead to skin irritation and brown yellow disease. Over the years, more and more new ingredients for safety have gradually faded out of the mainstream market.Arbutin is a major improved component ( derivative of hydroquinone ) after hydroquinone. It plays a role by competitively binding active sites and simulating L-tyrosine. It is safer than hydroquinone. It is also clinically confirmed that it is effective for pigmentation. Generally, α-arbutin is preferred in products. It has a better structure, is very stable, and is not easily hydrolyzed by skin. Hydroquinone can only be detected under extreme conditions ( such as strong acid and alkali, extremely high temperature ). However, its efficacy is controversial. In clinical observation, long-term use of α-arbutin can indeed improve pigmentation, but in its cell or enzyme level test, the inhibition rate of arbutin on tyrosinase is not so good. Its brightening effect may not only rely on the inhibition of tyrosinase, but also may involve bypass mechanisms such as anti-inflammatory, anti-oxidation, and regulation of melanin transport. From the experimental results, it has a good effect on preventing pigmentation and brightening the overall skin color, but it has a limited effect on the formation of deep dermal spots ( such as chloasma ).

Novel synthetic inhibitors reflect researchers’ new discoveries and the emerging research directions they are pursuing. Take KT‑939 as an example: existing studies confirm its potent inhibitory effect on human tyrosinase with an extremely low IC₅₀ value of 0.36 μM. Its efficacy is approximately 3.6 times higher than Thiamidol (IC₅₀: 1.3 μM) and vastly superior to alternatives such as 4‑butylresorcinol (IC₅₀: 8.0 μM). At the cellular level, KT‑939 effectively blocks melanin biosynthesis at ultra‑low dosages, and clinical trials verify its favorable skin tolerance, being four times safer than hydroquinone. It embodies an innovative R&D shift from single-target tyrosinase inhibition toward multi-targeted, multifunctional inhibitors.

Beyond suppressing tyrosinase activity, such novel ingredients deliver synergistic brightening benefits by activating the NRF2/ARE antioxidant pathway and inhibiting pro-inflammatory cytokines including IL-6, IL-1α and TNF-α. The development of next-generation inhibitors primarily focuses on precisely targeting the active site of human tyrosinase while inducing favorable conformational changes for enzyme inhibition. Scientists continuously optimize molecular structures via compound screening, molecular simulation and biological testing to balance inhibitory potency and biosafety. Meanwhile, advanced delivery systems including nanocarriers and liposomes are developed to elevate bioavailability, facilitating better skin penetration and efficacy of active substances. Nevertheless, as a newly developed synthetic compound, the long-term safety profile of KT‑939 remains to be further validated.

Naturally derived inhibitors have become a highly popular research direction in recent years, featuring core strengths of natural origin and low side effects that align with modern consumers’ pursuit of natural skincare. A typical example is glabridin extracted from the root of Glycyrrhiza glabra (licorice). Initially, manufacturers targeted glycyrrhizic acid for anti‑inflammatory and antitussive applications, while glabridin was merely an overlooked by‑product of the extraction process. Possessing a unique isoflavone chemical skeleton, glabridin exhibits potent bioactivity. Given its isoflavone structure, researchers speculated its skincare potential, which has been validated by experiments: it achieves brightening efficacy through competitive tyrosinase inhibition. However, glabridin only accounts for 0.1%–0.3% of licorice root by weight. Its drawbacks including low content, complicated extraction procedures, high production cost and insufficient stability restrict large‑scale commercialization. Such bottlenecks also hinder the widespread use of most naturally sourced brightening ingredients.

From laboratory benches to vanity countertops, brightening ingredients acting via the tyrosinase-inhibitory pathway have evolved from potent yet high-risk options toward highly effective and safer alternatives. Limitations of traditional inhibitors have driven the exploration of novel synthetic and naturally derived inhibitors, while precise molecular design including active-site optimization and multi-pathway synergism delivers longer-lasting and milder brightening effects. Moving forward, we aim to keep optimizing molecular structures and delivery systems to bring more targeted, efficient and safe active ingredients into daily skincare routines.